Strength of the Saudi Arabian Economy:
Active Pharmaceutical Ingredients

Saudi Arabia (KSA) is an increasingly attractive investment destination with the Kingdom’s economy ranked 16th among G20 countries and 18th globally, with a GDP of $1.01 trillion in 2022 according to IMF estimations. The demand of pharmaceutical products across the value chain is expected to rise rapidly in the MENA region, with KSA being a key market. While API manufacturing is still at its nascent stage in the MENA region with few manufacturers spread across, there are several well-established, large-scale drug formulators present in KSA, Egypt, Jordan, and other countries within MENA. This executive brief will provide insight into how the Kingdom of Saudi Arabia’s economy is growing and, specifically in the Active Pharmaceutical Ingredients industry.